Ask
Search
My library
ORKG

ORKG Ask

Our mission is to organize scholarly knowledge and make it accessible to humans and machines.

About

About ORKG Ask
Report issue
Statistics
Contact

Legal

Terms of use
Data protection (sheet)
Imprint
Accessibility
License

Technical

We
open source
System status
Changelog
Frontend: v1.41.0
Backend: v1.13.4

We use cookies to provide a better user experience.

Data Protection

Average GI<sub>50</sub> and TGI values for lapatinib in 22 HER2 positive breast cancer cell lines.

James E. Korkola (771288)
Eric A. Collisson (662838)
Laura Heiser (771289)
Chris Oates (771290)
Nora Bayani (771291)
Sleiman Itani (771292)
Amanda Esch (771293)
Wallace Thompson (771294)
Obi L. Griffith (63659)
Nicholas J. Wang (771295)
Wen-Lin Kuo (184234)
Brian Cooper (771296)
Jessica Billig (771297)
Safiyyah Ziyad (771298)
Jenny L. Hung (771299)
Lakshmi Jakkula (771300)
Heidi Feiler (771301)
Yiling Lu (155900)
Gordon B. Mills (120313)
Paul T. Spellman (116204)
Claire Tomlin (771302)
Sach Mukherjee (19432)
Joe W. Gray (116206)

Publication date

July 2015

DOI

10.1371/journal.pone.0133219.t001

Abstract

<p>Average GI<sub>50</sub> and TGI values for lapatinib in 22 HER2 positive breast cancer cell lines.</p

Extracted data

Related items

HER2 amplification pattern and gene copy number in cells resistant to lapatinib or T-DM1.

Rocio Vicario (754737)
Vicente Peg (466433)
Beatriz Morancho (754738)
Mariano Zacarias-Fluck (754739)
Junjie Zhang (355622)
Águeda Martínez-Barriocanal (732632)
Alexandra Navarro Jiménez (754740)
Claudia Aura (754741)
Octavio Burgues (754742)
Ana Lluch (103419)
Javier Cortés (426507)
Paolo Nuciforo (232247)
Isabel T. Rubio (754743)
Elisabetta Marangoni (655592)
James Deeds (754744)
Markus Boehm (754745)
Robert Schlegel (118906)
Josep Tabernero (237681)
Rebecca Mosher (754746)
Joaquín Arribas (754747)

June 2015

<p>A, Schematic showing the procedure to obtain cells resistant to anti-HER2 therapies <i>in vitro</...

Eight out of fourteen evaluable advanced breast cancer patients demonstrated a consistent or increased quantity of CTCs in 7.5 ml blood following the first cycle of Lapatinib treatment.

Justin Stebbing (181883)
Rachel Payne (410256)
Justine Reise (410257)
Adam E. Frampton (181831)
Miranda Avery (410258)
Laura Woodley (410259)
Angelo Di Leo (410260)
Marta Pestrin (20341)
Jonathan Krell (181848)
R. Charles Coombes (410261)

May 2013

<p>Graphs show CTC measurements and EGFR positivity at screening or baseline and at follow-up after ...

GI<sub>50</sub> values and Rc0.1 values of the compounds for treatment of cancer cell lines.

Shinsuke Araki (491598)
Ryo Dairiki (683049)
Yusuke Nakayama (683050)
Aiko Murai (683051)
Risa Miyashita (683052)
Misa Iwatani (683053)
Toshiyuki Nomura (683054)
Osamu Nakanishi (683055)

January 2015

<p>The GI<sub>50</sub> value represents the concentration required to achieve 50% growth inhibition....

LAPATINIB IN BREAST CANCER – THE PREDICTIVE SIGNIFICANCE OF HER1 (EGFR), HER2, PTEN AND PIK3CA GENES AND LAPATINIB PLASMA LEVEL ASSESSMENT

Katerina Bouchalovaa
Magdalena Cizkovaa
Karel Cwiertkab
Radek Trojaneca
David Friedeckyc
Marian Hajducha

September 2016

therapy/Biological therapy/Metastatic breast cancer/Lapatinib plasma level Background. Breast cancer...

The relationship between lapatinib concentrations in tumor and plasma from clinical samples.

Neil L. Spector (523233)
Faith C. Robertson (827073)
Sarah Bacus (29270)
Kimberly Blackwell (94641)
Deborah A. Smith (193779)
Kelli Glenn (827074)
Leanne Cartee (827075)
Jennifer Harris (827076)
Carie L. Kimbrough (827077)
Mark Gittelman (827078)
Eli Avisar (827079)
Peter Beitsch (827080)
Kevin M. Koch (820458)

November 2015

<p>Women with early stage HER2+ breast cancer were randomized to oral lapatinib monotherapy at 500 m...

Her3 overexpression confers tumor cell growth under lapatinib.

Navneet Singh (5174126)
Lindsey Romick-Rosendale (14237679)
Miki Watanabe-Chailland (7463153)
Lisa M. Privette Vinnedge (9644921)
Kakajan Komurov (28703)

December 2022

A) Total and phospho-Her3 levels at the indicated stages of lapatinib (1μM) treatment. B) Western bl...

Median (range) of lapatinib concentrations in tumor, plasma, and their ratios.

Neil L. Spector (523233)
Faith C. Robertson (827073)
Sarah Bacus (29270)
Kimberly Blackwell (94641)
Deborah A. Smith (193779)
Kelli Glenn (827074)
Leanne Cartee (827075)
Jennifer Harris (827076)
Carie L. Kimbrough (827077)
Mark Gittelman (827078)
Eli Avisar (827079)
Peter Beitsch (827080)
Kevin M. Koch (820458)

November 2015

<p>Median (range) of lapatinib concentrations in tumor, plasma, and their ratios.</p

Lapatinib interrupts the interaction between BRCA1 and EGFR in triple negative breast cancer cell lines.

Somaira Nowsheen (127688)
Tiffiny Cooper (127691)
Jennifer A. Stanley (127693)
Eddy S. Yang (127697)

October 2012

<p>(A–B) Reciprocal immunoprecipitation with (A) EGFR and (B) BRCA1 was performed in (from left to r...

Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial

A. Decensi
M. Puntoni
G. Pruneri
A. Guerrieri-Gonzaga
M. Lazzeroni
D. Serrano
D. Macis
H. Johansson
O. Pala
A. Luini
P. Veronesi
V. Galimberti
M.C. Dotti
G. Viale
B. Bonanni

August 2011

Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor l...

The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.

Justin Stebbing
Rachel Payne
Justine Reise
Adam E Frampton
Miranda Avery
Laura Woodley
Angelo Di Leo
Marta Pestrin
Jonathan Krell
R Charles Coombes

Analysis of circulating tumor cells (CTCs) provides real-time measures of cancer sub-populations wit...

Median of percentage IGF-IR and VEGFR-2 expression on the CETCs in 50 breast cancer patients.

Monika Pizon (283886)
Dorothea Sonja Zimon (283890)
Ulrich Pachmann (283894)
Katharina Pachmann (15479)

February 2013

<p>Median of percentage IGF-IR and VEGFR-2 expression on the CETCs in 50 breast cancer patients.</p

Lapatinib works in conjunction with Th1 cytokines to suppress metabolic activity of breast cancer cell lines.

Loral E. Showalter (4170238)
Crystal Oechsle (6243821)
Nirmala Ghimirey (6243824)
Chase Steele (6243827)
Brian J. Czerniecki (285700)
Gary K. Koski (285702)

January 2019

Cultured SK-BR-3, BT-474 and MDA-MB-468 cells were treated either with Th1 cytokines (TNF-α plus IFN...

Six out of fourteen evaluable advanced breast cancer patients demonstrated a decrease in the quantity of CTCs in 7.5 ml blood following the first cycle of Lapatinib treatment.

Justin Stebbing (181883)
Rachel Payne (410256)
Justine Reise (410257)
Adam E. Frampton (181831)
Miranda Avery (410258)
Laura Woodley (410259)
Angelo Di Leo (410260)
Marta Pestrin (20341)
Jonathan Krell (181848)
R. Charles Coombes (410261)

May 2013

<p>Graphs show CTC measurements and EGFR positivity at screening or baseline and at follow-up after ...

Additional file 1 of A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer

Gang Ning (531332)
Qihui Zhu (388528)
Wonyoung Kang (11283112)
Hamin Lee (11283115)
Leigh Maher (11283118)
Yun-Suhk Suh (5566886)
Michael Michaud (291858)
Mayerlin Silva (11283121)
Jee Young Kwon (3342710)
Chengsheng Zhang (203519)
Charles Lee (14206)

August 2021

Additional file 1: Fig. S1. (A) CRISPR-Cas9 library sequencing data analysis workflow. (B) The distr...

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer

Agelaki Sofia
Kalykaki Antonia
Markomanolaki Harris
Papadaki Maria A.
Kallergi Galatea
Hatzidaki Dora
Kalbakis Kostas
Mavroudis Dimitrios
Georgoulias Vassilis

June 2015

To evaluate the efficacy of lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, in therapy-re...

HER2 amplification pattern and gene copy number in cells resistant to lapatinib or T-DM1.

Rocio Vicario (754737)
Vicente Peg (466433)
Beatriz Morancho (754738)
Mariano Zacarias-Fluck (754739)
Junjie Zhang (355622)
Águeda Martínez-Barriocanal (732632)
Alexandra Navarro Jiménez (754740)
Claudia Aura (754741)
Octavio Burgues (754742)
Ana Lluch (103419)
Javier Cortés (426507)
Paolo Nuciforo (232247)
Isabel T. Rubio (754743)
Elisabetta Marangoni (655592)
James Deeds (754744)
Markus Boehm (754745)
Robert Schlegel (118906)
Josep Tabernero (237681)
Rebecca Mosher (754746)
Joaquín Arribas (754747)

June 2015

<p>A, Schematic showing the procedure to obtain cells resistant to anti-HER2 therapies <i>in vitro</...

Eight out of fourteen evaluable advanced breast cancer patients demonstrated a consistent or increased quantity of CTCs in 7.5 ml blood following the first cycle of Lapatinib treatment.

Justin Stebbing (181883)
Rachel Payne (410256)
Justine Reise (410257)
Adam E. Frampton (181831)
Miranda Avery (410258)
Laura Woodley (410259)
Angelo Di Leo (410260)
Marta Pestrin (20341)
Jonathan Krell (181848)
R. Charles Coombes (410261)

May 2013

<p>Graphs show CTC measurements and EGFR positivity at screening or baseline and at follow-up after ...

GI<sub>50</sub> values and Rc0.1 values of the compounds for treatment of cancer cell lines.

Shinsuke Araki (491598)
Ryo Dairiki (683049)
Yusuke Nakayama (683050)
Aiko Murai (683051)
Risa Miyashita (683052)
Misa Iwatani (683053)
Toshiyuki Nomura (683054)
Osamu Nakanishi (683055)

January 2015

<p>The GI<sub>50</sub> value represents the concentration required to achieve 50% growth inhibition....

LAPATINIB IN BREAST CANCER – THE PREDICTIVE SIGNIFICANCE OF HER1 (EGFR), HER2, PTEN AND PIK3CA GENES AND LAPATINIB PLASMA LEVEL ASSESSMENT

Katerina Bouchalovaa
Magdalena Cizkovaa
Karel Cwiertkab
Radek Trojaneca
David Friedeckyc
Marian Hajducha

September 2016

therapy/Biological therapy/Metastatic breast cancer/Lapatinib plasma level Background. Breast cancer...

The relationship between lapatinib concentrations in tumor and plasma from clinical samples.

Neil L. Spector (523233)
Faith C. Robertson (827073)
Sarah Bacus (29270)
Kimberly Blackwell (94641)
Deborah A. Smith (193779)
Kelli Glenn (827074)
Leanne Cartee (827075)
Jennifer Harris (827076)
Carie L. Kimbrough (827077)
Mark Gittelman (827078)
Eli Avisar (827079)
Peter Beitsch (827080)
Kevin M. Koch (820458)

November 2015

<p>Women with early stage HER2+ breast cancer were randomized to oral lapatinib monotherapy at 500 m...

Her3 overexpression confers tumor cell growth under lapatinib.

Navneet Singh (5174126)
Lindsey Romick-Rosendale (14237679)
Miki Watanabe-Chailland (7463153)
Lisa M. Privette Vinnedge (9644921)
Kakajan Komurov (28703)

December 2022

A) Total and phospho-Her3 levels at the indicated stages of lapatinib (1μM) treatment. B) Western bl...

Median (range) of lapatinib concentrations in tumor, plasma, and their ratios.

Neil L. Spector (523233)
Faith C. Robertson (827073)
Sarah Bacus (29270)
Kimberly Blackwell (94641)
Deborah A. Smith (193779)
Kelli Glenn (827074)
Leanne Cartee (827075)
Jennifer Harris (827076)
Carie L. Kimbrough (827077)
Mark Gittelman (827078)
Eli Avisar (827079)
Peter Beitsch (827080)
Kevin M. Koch (820458)

November 2015

<p>Median (range) of lapatinib concentrations in tumor, plasma, and their ratios.</p

Lapatinib interrupts the interaction between BRCA1 and EGFR in triple negative breast cancer cell lines.

Somaira Nowsheen (127688)
Tiffiny Cooper (127691)
Jennifer A. Stanley (127693)
Eddy S. Yang (127697)

October 2012

<p>(A–B) Reciprocal immunoprecipitation with (A) EGFR and (B) BRCA1 was performed in (from left to r...

Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial

A. Decensi
M. Puntoni
G. Pruneri
A. Guerrieri-Gonzaga
M. Lazzeroni
D. Serrano
D. Macis
H. Johansson
O. Pala
A. Luini
P. Veronesi
V. Galimberti
M.C. Dotti
G. Viale
B. Bonanni

August 2011

Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor l...

The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.

Justin Stebbing
Rachel Payne
Justine Reise
Adam E Frampton
Miranda Avery
Laura Woodley
Angelo Di Leo
Marta Pestrin
Jonathan Krell
R Charles Coombes

Analysis of circulating tumor cells (CTCs) provides real-time measures of cancer sub-populations wit...

Median of percentage IGF-IR and VEGFR-2 expression on the CETCs in 50 breast cancer patients.

Monika Pizon (283886)
Dorothea Sonja Zimon (283890)
Ulrich Pachmann (283894)
Katharina Pachmann (15479)

February 2013

<p>Median of percentage IGF-IR and VEGFR-2 expression on the CETCs in 50 breast cancer patients.</p

Lapatinib works in conjunction with Th1 cytokines to suppress metabolic activity of breast cancer cell lines.

Loral E. Showalter (4170238)
Crystal Oechsle (6243821)
Nirmala Ghimirey (6243824)
Chase Steele (6243827)
Brian J. Czerniecki (285700)
Gary K. Koski (285702)

January 2019

Cultured SK-BR-3, BT-474 and MDA-MB-468 cells were treated either with Th1 cytokines (TNF-α plus IFN...

Six out of fourteen evaluable advanced breast cancer patients demonstrated a decrease in the quantity of CTCs in 7.5 ml blood following the first cycle of Lapatinib treatment.

Justin Stebbing (181883)
Rachel Payne (410256)
Justine Reise (410257)
Adam E. Frampton (181831)
Miranda Avery (410258)
Laura Woodley (410259)
Angelo Di Leo (410260)
Marta Pestrin (20341)
Jonathan Krell (181848)
R. Charles Coombes (410261)

May 2013

<p>Graphs show CTC measurements and EGFR positivity at screening or baseline and at follow-up after ...

Additional file 1 of A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer

Gang Ning (531332)
Qihui Zhu (388528)
Wonyoung Kang (11283112)
Hamin Lee (11283115)
Leigh Maher (11283118)
Yun-Suhk Suh (5566886)
Michael Michaud (291858)
Mayerlin Silva (11283121)
Jee Young Kwon (3342710)
Chengsheng Zhang (203519)
Charles Lee (14206)

August 2021

Additional file 1: Fig. S1. (A) CRISPR-Cas9 library sequencing data analysis workflow. (B) The distr...

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer

Agelaki Sofia
Kalykaki Antonia
Markomanolaki Harris
Papadaki Maria A.
Kallergi Galatea
Hatzidaki Dora
Kalbakis Kostas
Mavroudis Dimitrios
Georgoulias Vassilis

June 2015

To evaluate the efficacy of lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, in therapy-re...

HER2 amplification pattern and gene copy number in cells resistant to lapatinib or T-DM1.

Rocio Vicario (754737)
Vicente Peg (466433)
Beatriz Morancho (754738)
Mariano Zacarias-Fluck (754739)
Junjie Zhang (355622)
Águeda Martínez-Barriocanal (732632)
Alexandra Navarro Jiménez (754740)
Claudia Aura (754741)
Octavio Burgues (754742)
Ana Lluch (103419)
Javier Cortés (426507)
Paolo Nuciforo (232247)
Isabel T. Rubio (754743)
Elisabetta Marangoni (655592)
James Deeds (754744)
Markus Boehm (754745)
Robert Schlegel (118906)
Josep Tabernero (237681)
Rebecca Mosher (754746)
Joaquín Arribas (754747)

June 2015

<p>A, Schematic showing the procedure to obtain cells resistant to anti-HER2 therapies <i>in vitro</...

Eight out of fourteen evaluable advanced breast cancer patients demonstrated a consistent or increased quantity of CTCs in 7.5 ml blood following the first cycle of Lapatinib treatment.

Justin Stebbing (181883)
Rachel Payne (410256)
Justine Reise (410257)
Adam E. Frampton (181831)
Miranda Avery (410258)
Laura Woodley (410259)
Angelo Di Leo (410260)
Marta Pestrin (20341)
Jonathan Krell (181848)
R. Charles Coombes (410261)

May 2013

<p>Graphs show CTC measurements and EGFR positivity at screening or baseline and at follow-up after ...

GI<sub>50</sub> values and Rc0.1 values of the compounds for treatment of cancer cell lines.

Shinsuke Araki (491598)
Ryo Dairiki (683049)
Yusuke Nakayama (683050)
Aiko Murai (683051)
Risa Miyashita (683052)
Misa Iwatani (683053)
Toshiyuki Nomura (683054)
Osamu Nakanishi (683055)

January 2015

<p>The GI<sub>50</sub> value represents the concentration required to achieve 50% growth inhibition....